Related Experiment Video
Updated: Aug 13, 2026
Myeloid Cell Isolation from Mouse Skin and Draining Lymph Node Following Intradermal Immunization with Live Attenuated Plasmodium Sporozoites
Published on: May 18, 2016
Oral vaccination of mice against rodent malaria with recombinant Lactococcus lactis expressing MSP-1(19)
Zhi-Hong Zhang1, Pei-Hong Jiang, Ning-Jun Li
1Department of Biochemistry, Fudan University, 220 Han Dan Road, Shanghai 200433, China.
Aim:
To construct the recombinant Lactococcus lactis as oral delivery vaccination against malaria.
Methods:
The C-terminal 19-ku fragments of MSP1 (MSP-1(19)) of Plasmodium yoelii 265-BY was expressed in L. lactis and the recombinant L. lactis was administered orally to BALB/c and C57BL/6 mice. After seven interval vaccinations within 4 wk, the mice were challenged with P. yoelii 265-BY parasites of erythrocytic stage. The protective efficacy of recombinant L. lactis was evaluated.
Results:
The peak parasitemias in average for the experiment groups of BALB/c and C57BL/6 mice were 0.8+/-0.4% and 20.8+/-26.5%, respectively, and those of their control groups were 12.0+/-0.8% and 60.8+/-9.6%, respectively. None of the BALB/c mice in both experimental group and control group died during the experiment. However, all the C57BL/6 mice in the control group died within 23 d and all the vaccinated mice survived well.
Conclusion:
The results imply the potential of recombinant L. lactis as oral delivery vaccination against malaria.
Insights
Recombinant Lactococcus lactis expressing Plasmodium yoelii MSP-1(19) shows potential as an oral malaria vaccine. Vaccinated mice demonstrated significant protection against malaria challenge, with improved survival rates in C57BL/6 mice.
Area of Science:
- Biotechnology
- Immunology
- Parasitology
Background:
- Malaria remains a significant global health burden, necessitating novel vaccine strategies.
- Oral vaccination offers advantages in administration and accessibility.
- Lactococcus lactis is a potential candidate for developing live oral vaccines.
Purpose of the Study:
- To engineer Lactococcus lactis for oral delivery of malaria antigens.
- To evaluate the efficacy of recombinant Lactococcus lactis as a malaria vaccine.
Main Methods:
- The C-terminal 19-ku fragment of Plasmodium yoelii merozoite surface protein 1 (MSP-1(19)) was expressed in Lactococcus lactis.
- Recombinant Lactococcus lactis was administered orally to BALB/c and C57BL/6 mice.
- Mice were challenged with Plasmodium yoelii and survival and parasitemia were monitored.
Main Results:
- Recombinant Lactococcus lactis significantly reduced peak parasitemia in vaccinated mice compared to controls.
- BALB/c mice showed minimal parasitemia in both experimental and control groups.
- C57BL/6 mice vaccinated with recombinant Lactococcus lactis survived the challenge, while all control mice died.
Conclusions:
- Recombinant Lactococcus lactis demonstrates potential as an effective oral vaccine delivery system against malaria.
- The study highlights the immunogenic properties of Plasmodium yoelii MSP-1(19) when delivered via Lactococcus lactis.
- Further research is warranted to optimize this oral vaccination strategy for malaria prevention.
